| Patient | Satchel Paige |
|---|---|
| Date of birth | 1953-07-07 |
| Identifiers | MRN HR-ML047-SYN; SSN (made up) 000-47-3381 |
| Document date | 2026-10-06 |
| Author | Delphine Whitaker-Osei, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Subsequent annual wellness visit, two weeks after an exacerbation. [S]
Mr. Paige, 73, comes for his subsequent annual wellness visit two weeks after a moderate COPD exacerbation; his last wellness visit was a year ago at his previous clinic. He finished the prednisone and doxycycline ten days ago and is back to his usual breathing, uses albuterol about once a day, and returned to pulmonary rehabilitation last week. He takes his umeclidinium-vilanterol every morning and atorvastatin every evening without muscle aches. He completed the health risk assessment beforehand. He wants all his vaccines today so that, in his words, the next cold does not knock him down. [S]
| Element | Detail |
|---|---|
| Visit | Subsequent annual wellness visit, age 73 |
| Active conditions | COPD, GOLD 2, group B, recovered from a moderate exacerbation; hyperlipidemia on atorvastatin; former smoker |
| Medicines | Umeclidinium-vilanterol daily; albuterol as needed; atorvastatin 20 mg |
| Mood and cognition | PHQ-2 0; Mini-Cog 5 |
Health risk assessment. Completed by the patient on paper in the waiting room and reviewed with him by Dr. Whitaker-Osei. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Fair to good; better since rehabilitation |
| Psychosocial | Lives with his wife; a large family nearby; active in his church; speaks at schools |
| Alcohol | A beer on a holiday; AUDIT-C 1 at intake |
| Tobacco | Former smoker, about 30 pack-years, stopped eleven years ago; no secondhand smoke at home |
| Physical activity | Pulmonary rehabilitation twice a week and walks on other days |
| Nutrition | Regular meals; weight steady |
| Sleep | Seven hours on two pillows by habit; no snoring reported |
| Safety at home | Smoke and carbon monoxide alarms; no firearms at home; gas stove used with the window open |
| Falls | No falls |
| Activities of daily living | Independent |
| Hearing and vision | Reading glasses; hearing good |
| Oral health | Dentures; dental visit this year |
| Cost and access | The maintenance inhaler is covered through his drug plan with a low copayment; rides to rehabilitation from a church volunteer |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever, weight loss or night sweats |
| Eyes | Negative | No change in vision |
| Ears, nose, mouth, and throat | Negative | Cold resolved |
| Respiratory | Positive | Usual breathlessness after a block; a little clear morning sputum; no wheeze |
| Cardiovascular | Negative | No chest pain, palpitations or ankle swelling |
| Gastrointestinal | Negative | No indigestion or change in bowel habit |
| Genitourinary | Negative | No hesitancy or poor stream on the inhaler |
| Musculoskeletal | Negative | No muscle aches on atorvastatin; old shoulder and arm stiffness only |
| Integumentary | Negative | No rashes |
| Neurological | Negative | No numbness, weakness or memory trouble |
| Psychiatric | Negative | Mood good; PHQ-2 0 |
11 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Albuterol 90 micrograms per inhalation metered-dose inhaler with a spacer, two inhalations every four hours as needed for breathlessness | Two inhalations with a spacer every 4 hours as needed | Respiratory tract route | 2026-07-14 | active | S |
| Umeclidinium 62.5 micrograms with vilanterol 25 micrograms dry powder inhaler (a LAMA with a LABA), one inhalation once a day | One inhalation each morning; a strong, deep breath in | Respiratory tract route | 2026-07-28 | active | S |
| Atorvastatin 20 mg tablet once a day | One tablet each evening | Oral route | 2026-07-14 | active | S |
| Prednisone 40 mg (two 20 mg tablets) by mouth each morning for five days | Two tablets each morning with food for five days | Oral route | 2026-09-22 to 2026-09-26 | completed | S |
| Doxycycline 100 mg capsule by mouth twice a day for five days | One capsule twice a day with a full glass of water, sitting up, for five days | Oral route | 2026-09-22 to 2026-09-26 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-06 | Body height | 191 | cm | S |
| 2026-10-06 | Body weight | 83 | kg | S |
| 2026-10-06 | Body mass index (BMI) [Ratio] | 22.8 | kg/m2 | S |
| 2026-10-06 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-10-06 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-10-06 | Heart rate | 76 | /min | S |
| 2026-10-06 | Respiratory rate | 16 | /min | S |
| 2026-10-06 | Body temperature | 36.6 | Cel | S |
| 2026-10-06 | Oxygen saturation in Arterial blood by Pulse oximetry | 95 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-06 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-10-06 | Total score [Mini-Cog] | 5 | {score} | S |
Vital signs recorded on 2026-10-06; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Well; weight 83.0 kg, BMI 22.8; blood pressure 128/76; pulse 76; oxygen saturation 95 percent on room air |
| Ears, nose, mouth, and throat | Throat normal; dentures fit well |
| Neck | No nodes; no raised jugular venous pressure |
| Respiratory | Reduced breath sounds at the bases; no wheeze or crackles |
| Cardiovascular | Regular rhythm; no murmur; no edema |
| Abdomen | Soft; no pulsatile mass |
| Musculoskeletal | Timed Up and Go 9 seconds |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Breathlessness on exertion for about two years, now after one flight of stairs or a block on the level (mMRC 2), with a morning cough and a little clear sputum most days; no chest pain, ankle swelling, orthopnea, wheeze at rest or weight loss; a former smoker of about 30 pack-years; cause under evaluation with spirometry and a pulmonology consultation | resolved | confirmed | R06.09 | S — Synthetic presenting problem anchored to his documented emphysema; superseded when spirometry at the consultation confirmed COPD. |
| Chronic obstructive pulmonary disease, GOLD grade 2 (post-bronchodilator FEV1/FVC 0.58, FEV1 61% predicted by the race-neutral GLI Global equations), GOLD group B (CAT 18, mMRC 2, no exacerbation in the past year); alpha-1 antitrypsin normal; blood eosinophils 0.08 x 10^3/uL; synthetic modern diagnosis linked to his documented emphysema | active | confirmed | J44.9 | S — Synthetic modern diagnosis made at the consultation, anchored to his documented emphysema; its onset and course in the modern episode are synthetic. |
| Former cigarette smoker, about 30 pack-years, stopped eleven years ago on his own; no use since | active | confirmed | Z87.891 | S — Synthetic smoking history: whether he smoked is not documented in the sources read, so the history is synthetic and labeled as such. |
| Hyperlipidemia: LDL 148 mg/dL, HDL 44 and triglycerides 160 at intake; estimated 10-year cardiovascular risk about 18 percent; atorvastatin started by shared decision | active | confirmed | E78.5 | S — Synthetic cardiovascular risk factor anchored to his documented heart trouble; not a claim about his real lipids. |
| Moderate exacerbation of COPD with a viral cold: more breathlessness, more sputum turning green, and wheeze for three days; oxygen saturation 92 percent; no pneumonia on chest X-ray; treated at home with prednisone and doxycycline; recovered | resolved | confirmed | J44.1 | S — Synthetic exacerbation at the sick visit; not a historical claim. |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Blood pressure screening | Completed today | 128/76 mmHg |
| Lipid management | Up to date | LDL 86 mg/dL on atorvastatin 20 mg four weeks ago |
| Diabetes screening | Up to date | HbA1c 5.6% at intake |
| Colorectal cancer screening | Up to date | Colonoscopy five years ago without polyps, reported by his previous clinic; further screening after 75 by shared decision |
| Lung cancer screening | Up to date | Low-dose CT nine weeks ago, Lung-RADS 2; next in one year |
| Abdominal aortic aneurysm screening | Ordered | One-time ultrasound for men 65 to 75 who have ever smoked |
| Prostate cancer screening | Not indicated | PSA screening is not recommended at 70 and older |
| Hepatitis C screening | Ordered | Once for adults; drawn today |
| Hepatitis B screening | Ordered | Triple panel once for all adults; drawn today |
| Osteoporosis screening | Not indicated | Evidence insufficient for screening men; one five-day steroid course does not change this; revisit if steroid courses recur |
| Depression screening | Completed today | PHQ-2 0 |
| Cognitive assessment | Completed today | Mini-Cog 5, normal |
| Unhealthy alcohol use | Up to date | AUDIT-C 1 at intake |
| Tobacco use | Completed today | Former smoker; remains smoke-free |
| Falls risk | Completed today | No falls; Timed Up and Go 9 seconds |
| Influenza vaccine | Completed today | High-dose vaccine today |
| RSV vaccine | Completed today | Single dose today, for an adult 50 to 74 with chronic lung disease |
| COVID-19 vaccine | Completed today | This season's vaccine today after discussion |
| Zoster vaccine | Completed today | First recombinant dose today; second in two to six months |
| Pneumococcal vaccine | Up to date | PCV20 at intake; no further dose needed |
| Tetanus, diphtheria, and pertussis | Up to date | Tdap at intake |
Immunizations given today: Influenza vaccine, high-dose, this season; Respiratory syncytial virus vaccine, single dose; COVID-19 mRNA vaccine, this season's formula; Recombinant zoster vaccine, dose 1 of 2 [S]
Guideline basis: Global Strategy for the Prevention, Diagnosis and Management of COPD: 2025 Report (2025); Lung Cancer: Screening (2021); Adult Immunization Schedule by Age (2026); Medicare Wellness Visits (Medicare Learning Network) (2026); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Abdominal Aortic Aneurysm: Screening (2019); Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations — United States, 2023 (2023)
Follow-up: Fifteen-week review in three weeks. Aortic ultrasound and hepatitis results by then. Second zoster dose in two to six months. Next wellness visit in one year. Next scheduled visit 2026-10-27: fifteen-week review after an exacerbation and pulmonary rehabilitation: symptoms, exacerbation history, GOLD group, oxygen, the action plan and the plan ahead. [S]
Voluntary advance care planning discussion of about 25 minutes, with his consent. He named a health care agent and a health care proxy form was completed; the agent is recorded in the chart and is not named here. He said that what matters most to him is staying at home in Kansas City, being with the people he loves, and still being able to talk with young players. If his lungs failed in a flare that could recover, he would accept a short trial of a breathing machine in intensive care, but not long-term life support if there were little chance of returning home. He will review these wishes with his family, and the plan will be revisited yearly or after any hospital stay. [S]